Drug development – The success of orphan drugs
Obtaining market approval is the ultimate goal for drug development companies - but few cross that finish line. However, over the past decade, there has been a positive trend in approval rates, especially for drugs that reach clinical phase III. The trend is particularly strong in one specific category – orphan drugs. This fifth and final part of BioStock's article series on drug development takes a closer look at orphan drug designation and its benefits, as well as some of its shortcomings.Read the article at biostock.se: https://www.biostock.se/en/2023/01/drug-development-the-success-